Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

PTC Therapeutics Inc. (PTCT)

54.34   1.52 (2.88%) 02-26 16:00
Open: 53.21 Pre. Close: 52.82
High: 55.44 Low: 53.01
Volume: 701,121 Market Cap: 3349M
PTC Therapeutics Inc is a biopharmaceutical company. It is focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 55.569 - 55.937 55.937 - 56.27
Low: 52.116 - 52.577 52.577 - 52.994
Close: 53.623 - 54.354 54.354 - 55.015

Technical analysis

as of: 2020-02-26 4:31:42 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 69.95     One year: 81.70
Support: Support1: 51.80    Support2: 46.80
Resistance: Resistance1: 59.89    Resistance2: 69.95
Pivot: 56.01
Moving Average: MA(5): 55.32     MA(20): 55.00
MA(100): 46.77     MA(250): 43.09
MACD: MACD(12,26): 1.06     Signal(9): 1.52
Stochastic oscillator: %K(14,3): 55.13     %D(3): 63.80
RSI: RSI(14): 49.92
52-week: High: 59.89  Low: 31.49  Change(%): 57.3
Average Vol(K): 3-Month: 80218  10-Days: 86362

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
PTCT has closed above bottom band by 28.2%. Bollinger Bands are 20.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arcus Biosciences Inc (NYSE: RCUS ) Ascendis Pharma A/S (NASDAQ: ASND ) AVITA MED LTD/S ADR (NASDAQ: RCEL )(reacted to its half-yearly results) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE )(said its therapeutic Immuno-STAT platform will be featured in a Merck & Co., Inc.'s (NYSE: MRK ) presentation at the Antigen Specific Immune Tolerance Drug Development Summit) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB )(reacted to its quarterly and full-year results) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc.

The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: AGRX ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptose Biosciences Inc (NASDAQ: APTO ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) Avrobio Inc (NASDAQ: AVRO ) Beam Therapeutics Inc (NASDAQ: BEAM ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) ChemoCentryx Inc (NASDAQ: CCXI ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fate Therapeutics Inc (NASDAQ: FATE ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) NeoGenomics, Inc. (NASDAQ: NEO ) Novartis AG (NYSE: NVS ) Ocular Therapeutix Inc (NASDAQ: OCUL ) PAVmed Inc (NASDAQ: PAVM ) Penumbra Inc (NYSE: PEN ) Prevail Therapeutics Inc (NASDAQ: PRVL )(reacted to the FDA according Orphan Drug Designation to its experimental gene therapy PR001 for treating Gaucher disease) PTC Therapeutics, Inc (NASDAQ: PTCT ) Repligen Corporation (NASDAQ: RGEN ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) West Pharmaceutical Services Inc.

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 61.63
Shares Float (M) 56.34
% Held by Insiders 3.19
% Held by Institutions 104.48
Shares Short (K) 3170
Shares Short P. Month (K)

Stock Financials

EPS -3.970
Book Value (p.s.) 10.780
PEG Ratio 1.69
Profit Margin -74.86
Operating Margin -53.23
Return on Assets (ttm) -7.4
Return on Equity (ttm) -42.3
Qtrly Rev. Growth 33.3
Gross Profit (p.s.) 1.299
Sales Per Share
EBITDA (p.s.) -2.082
Qtrly Earnings Growth
Operating Cash Flow (M) -103.58
Levered Free Cash Flow (M) -52.40

Stock Valuations

P/E -13.69
P/E Growth Ratio 0.03
P/BV 5.04
P/S 10.23
P/CF -32.33

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.